Cambridge Innovation Capital has backed a round sized at up to $50m for disease testing kit producer Sense Biodetection, which has now raised more than $64m altogether.

UK-based infection diagnostics kit producer Sense Biodetection has secured up to $50m in commitments from investors including Cambridge Innovation Capital, the venture capital investor focused on the Cambridge, UK ecosystem.
The round includes £900,000 ($1.2m) from commercialisation firm Mercia Asset Management and further participation from KDT Sense Holdings, Earlybird Health and private investors including Jonathan Milner.
Founded in 2014, Sense Bio supplies medical centres with diagnostic tests intended to match the efficacy of laboratory assays within handheld form…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?